上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
Tasisulam (Synonyms: LY 573636) 纯度: 99.13%
Tasisulam 是一种小分子抗肿瘤药物,通过内在途径诱导细胞凋亡,导致细胞色素 c 释放和 caspase 依赖性细胞死亡。Tasisulam 可以抑制有丝分裂进程并诱导血管正常化。
Tasisulam Chemical Structure
CAS No. : 519055-62-0
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
Free Sample (0.1-0.5 mg) | Apply now | ||
10 mM * 1 mL in DMSO | ¥720 | In-stock | |
10 mg | ¥650 | In-stock | |
25 mg | ¥1500 | In-stock | |
50 mg | ¥2600 | In-stock | |
100 mg | 询价 | ||
200 mg | 询价 |
* Please select Quantity before adding items.
Tasisulam 相关产品
•相关化合物库:
- Drug Repurposing Compound Library Plus
- Clinical Compound Library Plus
- Bioactive Compound Library Plus
- Apoptosis Compound Library
- Anti-Cancer Compound Library
- Clinical Compound Library
- Drug Repurposing Compound Library
生物活性 |
Tasisulam is a anticancer agent and induces apoptosis via the intrinsic pathway, resulting in cytochrome c release and caspase-dependent cell death. Tasisulam inhibits mitotic progression and induces vascular normalization[1]. |
||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
体外研究 (In Vitro) |
Tasisulam (200 nM-200 μM; 48 hours) induces an antiproliferative response across a wide range of tumor histologies with EC50s of 10 μM and 25 μM for Calu-6 and A-375 cell lines, respectively[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation Assay[1]
Cell Cycle Analysis[1]
Apoptosis Analysis[1]
|
||||||||||||||||||||||||
Clinical Trial |
|
||||||||||||||||||||||||
分子量 |
415.11 |
||||||||||||||||||||||||
Formula |
C11H6BrCl2NO3S2 |
||||||||||||||||||||||||
CAS 号 |
519055-62-0 |
||||||||||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||||||||||
储存方式 |
|
||||||||||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 250 mg/mL (602.25 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||||||||||
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务